These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 18575860

  • 1. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Sommer C, Lackner H, Benesch M, Sovinz P, Schwinger W, Moser A, Bergloeff J, Gruber A, Urban C.
    Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
    [Abstract] [Full Text] [Related]

  • 2. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
    Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C.
    Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
    [Abstract] [Full Text] [Related]

  • 3. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M.
    Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
    Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, Klenke R, Berg SL, Blaney SM.
    J Clin Oncol; 2004 Oct 01; 22(19):3916-21. PubMed ID: 15459213
    [Abstract] [Full Text] [Related]

  • 5. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
    Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, Gadner H, Urban C.
    J Pediatr Hematol Oncol; 2007 Apr 01; 29(4):222-6. PubMed ID: 17414563
    [Abstract] [Full Text] [Related]

  • 6. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
    Sancho JM, Morgades M, Arranz R, Fernández-Abellán P, Deben G, Alonso N, Blanes M, Rodríguez MJ, Nicolás C, Sánchez E, Fernández de Sevilla A, Conde E, Ribera JM, QUIT Study (PETHEMA, GELTAMO and GOTEL Groups).
    Med Clin (Barc); 2008 Oct 04; 131(11):401-5. PubMed ID: 18928719
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
    Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, Rambaldi A.
    Haematologica; 2015 Jun 04; 100(6):786-93. PubMed ID: 25749825
    [Abstract] [Full Text] [Related]

  • 8. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S, Mizoguchi H, Tomonaga M, Kanamaru A, Tsukagoshi S, Nakamura T, Ohashi Y, Yoshida S, Ohno R.
    Gan To Kagaku Ryoho; 1998 Dec 04; 25(14):2229-42. PubMed ID: 9881080
    [Abstract] [Full Text] [Related]

  • 9. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
    Sancho JM, Deben G, Parker A, Piñana JL, Bolam S, Sánchez-García E, Giménez E, Pascual T, Fernández-Abellán P, Palomera L, Ribera JM.
    Int J Hematol; 2007 Jul 04; 86(1):33-6. PubMed ID: 17675264
    [Abstract] [Full Text] [Related]

  • 10. Cytarabine dose for acute myeloid leukemia.
    Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.
    N Engl J Med; 2011 Mar 17; 364(11):1027-36. PubMed ID: 21410371
    [Abstract] [Full Text] [Related]

  • 11. Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
    Segot A, Raffoux E, Lengline E, Thieblemont C, Dombret H, Boissel N, Cluzeau T.
    Ann Hematol; 2015 Nov 17; 94(11):1859-63. PubMed ID: 26280395
    [Abstract] [Full Text] [Related]

  • 12. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
    Sancho JM, Ribera JM, Romero MJ, Martín-Reina V, Giraldo P, Ruiz E.
    Haematologica; 2006 Mar 17; 91(3):ECR02. PubMed ID: 16533729
    [Abstract] [Full Text] [Related]

  • 13. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
    Stacchini A, Demurtas A, Aliberti S.
    Cytometry B Clin Cytom; 2012 Sep 17; 82(5):280-2. PubMed ID: 22539249
    [Abstract] [Full Text] [Related]

  • 14. [Central nervous system involvement in adult acute leukemia].
    Sasaki H, Maekawa I, Kawamura S, Miyake T.
    Gan No Rinsho; 1984 Mar 17; 30(3):221-5. PubMed ID: 6585574
    [Abstract] [Full Text] [Related]

  • 15. Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration.
    Butto A, Al-Holou WN, Junck L, Sagher O, Fletcher JJ.
    J Clin Neurosci; 2011 Oct 17; 18(10):1417-8. PubMed ID: 21764318
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
    Valentin A, Troppan K, Pfeilstöcker M, Nösslinger T, Linkesch W, Neumeister P.
    Leuk Lymphoma; 2014 Aug 17; 55(8):1739-42. PubMed ID: 24138308
    [Abstract] [Full Text] [Related]

  • 17. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
    Jurczak W, Kroll-Balcerzak R, Giebel S, Machaczka M, Giza A, Ogórka T, Fornagiel S, Rybka J, Wróbel T, Kumiega B, Skotnicki AB, Komarnicki M.
    Med Oncol; 2015 Apr 17; 32(4):90. PubMed ID: 25716885
    [Abstract] [Full Text] [Related]

  • 18. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma.
    Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M, Zanet E, Lleshi A, Canzonieri V, Bulian P, Tirelli U.
    Cancer; 2010 Mar 15; 116(6):1495-501. PubMed ID: 20108270
    [Abstract] [Full Text] [Related]

  • 19. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature.
    Seif AE, Reilly AF, Rheingold SR.
    J Pediatr Hematol Oncol; 2010 Nov 15; 32(8):e349-52. PubMed ID: 20962675
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.